GSK, the tenth biggest pharmaceutical company in the world, is investing £50 million to establish the GSK–Oxford Cancer Immuno-Prevention Programme, aimed at advancing the development of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback